← Back to all signals
RESEARCH PAPER ANALYSIS

Assessing P1NP/β-CTX as Potential Risk Factors Associated With Different Subtypes of Fragile Hip Fracture in Elderly Patients.

This case-control study of 83 elderly patients found that higher serum P1NP and lower trochanter/total-hip BMD were associated with intertrochanteric (trochanteric) versus femoral neck fragile hip fractures, with P1NP identified as an independent risk factor for trochanteric fractures.

PMID41914012
JournalOrthopaedic surgery
Publication Date2026-03-31
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This case-control study of 83 elderly patients found that higher serum P1NP and lower trochanter/total-hip BMD were associated with intertrochanteric (trochanteric) versus femoral neck fragile hip fractures, with P1NP identified as an independent risk factor for trochanteric fractures.

WHY IT MATTERS

Research significance

The paper has minimal direct relevance to Parkinson's therapeutic discovery, but the results could help in fracture-risk stratification and perioperative management of older people with Parkinson's—who are at higher fall/hip-fracture risk—rather than informing molecular drug targets.

ABSTRACT

Source abstract

OBJECTIVE: Identifying the risk factor for occurrence of trochanteric/femoral neck fractures has always been difficult and crucial for prognosis of the diseases. The goal of this study is to evaluate the difference of P1NP/β-CTX between trochanteric and femoral neck fractures and establish these two BTMs as independent risk factors for these two subtypes of hip fractures in the elderly. METHODS: Following case-control study design, 83 elderly patients with fragile hip fractures from two tertiary hospitals recruited between February 2023 to August 2024 were assigned into intertrochanteric fracture group (42 cases) and femoral neck fracture group (41 cases). Baseline characteristics including age, sex, height, weight, BMI, and history of diabetes/Parkinson's disease were collected after admission. Besides, P1NP/β-CTX/PTH/25(OH)D blood tests and dual energy x-ray absorptiometry (DXA) were performed on all participants before surgical operation. The statistical significances of categorical variables and continuous variables were established through χ2-tests and independent samples t-tests, respectively. Multivariable logistic regression analysis was applied to detect potential associations between the selected variables and hip fracture subtype. RESULTS: The difference in P1NP between the trochanteric fracture group and femoral neck fracture groups is statistically significant. Specifically, patients with trochanteric fractures showed a markedly higher value of P1NP than those with femoral neck fractures (p = 0.044). However, no significant difference was observed for β-CTX between the two groups (p = 0.941). Furthermore, BMDs at trochanter and total hip regions in the trochanteric fracture group were significantly lower than those in the femoral neck fracture group (p = 0.028; p = 0.022). After multifactorial logistic regression, P1NP, weight, and female were stronger risk factors for trochanteric fracture (OR 0.969, 95% CI 0.948-0.990, p = 0.004; OR 0.531, 95% CI 0.284-0.992, p = 0.047; OR 0.082, 95% CI 0.008-0.837, p = 0.035), while height was found to be independently associated with femoral neck fracture (OR 1.715, 95% CI 1.023-2.874, p = 0.041). CONCLUSIONS: Compared with femoral neck fractures, P1NP was established as an independent risk factor for trochanteric fractures, suggesting the great potential of this BTM as a predictive indicator and postoperative complication monitor for trochanteric fractures.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic